Yttrium-90 glass microspheres radioembolization (RE) for biliary tract cancer: a large single-center experience
- 177 Downloads
Radioembolization (RE) is a promising treatment option for biliary tract cancers (BTC). We report here the largest series to date using this treatment modality.
We retrospectively studied data from 64 patients treated outside prospective clinical trial at our institution. We studied baseline characteristics as potential prognostic factors. We studied dose delivered to the tumor as predictive factors of outcomes in patients not receiving concomitant chemotherapy.
The Progression-Free Survival and Overall Survival (OS) were 7.6 months [95% Confidence Interval (CI): 4.6–10.6] and 16.4 months [95% CI: 7.8–25.0] in the whole cohort. The factors independently associated with OS in multivariable analysis were the primary localization of ICC (HR = 0.27, 95% CI: 0.11–0.68, p = 0.005) and a PS > 0 (HR = 2.21, 95% CI: 1.11–4.38, p = 0.024). During follow-up, 12 patients (19%) underwent surgery following downstaging, with a median OS of 51.9 months. In patients not treated with concomitant chemotherapy (n = 31), OS was significantly higher in patients with a dose delivered to the tumor 260Gy or higher than in patients with a dose delivered to the tumor lower than 260Gy (median 28.2 vs 11.4 months, log-rank p = 0.019).
Our results confirm that RE is a promising treatment modality in BTC. A high proportion of patients could be downstaged to surgery, with promising long-term survival. Dose delivered to the tumor correlated with clinical outcomes when chemotherapy was not used concomitantly.
KeywordsRadioembolization Dosimetry Biliary tract cancer 90Y Intrahepatic cholangiocarcinoma
This work was supported in part by a grant from the French National Agency for Research called “Investissements d’Avenir” n°ANR-11-LABX-0018-01.
Compliance with ethical standards
Conflict of interests
Etienne Garin, Yan Rolland and Julien Edeline are consultants for BTG, manufacturer of glass microspheres.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.
- 10.Camacho JC, Kokabi N, Xing M, Prajapati HJ, El-Rayes B, Kim HS. Modified response evaluation criteria in solid tumors and European Association for the Study of the liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization. J Vasc Interv Radiol JVIR. 2014;25:256–65.CrossRefGoogle Scholar
- 15.Reimer P, Virarkar MK, Binnenhei M, Justinger M, Schön MR, Tatsch K. Prognostic factors in overall survival of patients with Unresectable intrahepatic cholangiocarcinoma treated by means of Yttrium-90 Radioembolization: results in therapy-Naïve patients. Cardiovasc Intervent Radiol 2018.Google Scholar
- 16.Swinburne NC, Biederman DM, Besa C, Tabori NE, Fischman AM, Patel RS, et al. Radioembolization for Unresectable intrahepatic cholangiocarcinoma: review of safety, response evaluation criteria in solid tumors 1.1 imaging response and survival. Cancer Biother Radiopharm. 2017;32:161–8.CrossRefGoogle Scholar
- 21.Manceau V, Palard X, Rolland Y, Pracht M, Le Sourd S, Laffont S, et al. A MAA-based dosimetric study in patients with intrahepatic cholangiocarcinoma treated with a combination of chemotherapy and90Y-loaded glass microsphere selective internal radiation therapy. Eur J Nucl Med Mol Imaging. 2018.Google Scholar
- 23.Garin E, Lenoir L, Rolland Y, Laffont S, Pracht M, Mesbah H, et al. Effectiveness of quantitative MAA SPECT/CT for the definition of vascularized hepatic volume and dosimetric approach: phantom validation and clinical preliminary results in patients with complex hepatic vascularization treated with yttrium-90-labeled microspheres. Nucl Med Commun. 2011;32:1245–55.CrossRefGoogle Scholar
- 25.Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer Oxf Engl 1990. 2009;45:228–47.Google Scholar
- 26.Beuzit L, Edeline J, Brun V, Ronot M, Guillygomarc’h A, Boudjema K, et al. Comparison of Choi criteria and response evaluation criteria in solid tumors (RECIST) for intrahepatic cholangiocarcinoma treated with glass-microspheres Yttrium-90 selective internal radiation therapy (SIRT). Eur J Radiol. 2016;85:1445–52.CrossRefGoogle Scholar
- 27.Primrose J et al. Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study. J Clin Oncol ASCO Meet Abstr. 2017;35:Abstr 4006.Google Scholar
- 28.Edeline J et al. Adjuvant GEMOX for biliary tract cancer: updated relapse-free survival and first overall survival results of the randomized PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial. ESMO Conf. 2017;Abstr LBA 29.Google Scholar
- 29.Rayar M, Sulpice L, Edeline J, Garin E, Levi Sandri GB, Meunier B, et al. Intra-arterial Yttrium-90 Radioembolization combined with systemic chemotherapy is a promising method for Downstaging Unresectable huge intrahepatic cholangiocarcinoma to surgical treatment. Ann Surg Oncol 2015.Google Scholar
- 33.Edeline J, Coulouarn C, Crouzet L, Pracht M, Lepareur N, Clément B, et al. Gemcitabine and oxaliplatin, but not sorafenib or paclitaxel, have a synergistic effect with yttrium-90 in reducing hepatocellular carcinoma and cholangiocarcinoma cell line viability. J Vasc Interv Radiol JVIR. 2015;26:1874–1878.e2.CrossRefGoogle Scholar
- 35.Edeline J et al. Selective Internal Radiation Therapy (SIRT) with Yttrium-90-glass-microspheres plus chemotherapy in first-line treatment of advanced cholangiocarcinoma (MISPHEC study). ESMO Conf. 2017;Abstr 771P.Google Scholar
- 36.Kloeckner R, Ruckes C, Kronfeld K, Wörns MA, Weinmann A, Galle PR, et al. Selective internal radiotherapy (SIRT) versus transarterial chemoembolization (TACE) for the treatment of intrahepatic cholangiocellular carcinoma (CCC): study protocol for a randomized controlled trial. Trials. 2014;15:311.CrossRefGoogle Scholar